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Figure: Percentage of features with ICC>0.9 for CT1 vs. CBCT-
1 and CBCT-1 vs. CBCT-2, displayed for each feature group.  
 
Conclusion: For 26% of the radiomics features there is good 
agreement between CT1 and CBCT. 81% of the image 
features show high correlation between CBCT-FX1 and CBCT-
FX2 where no large differences are expected. In the future, 
radiomic features derived from CBCT images will be 
investigated to monitor changes of CBCT features over the 
course of treatment. One has to be careful with mixing 
radiomic features derived on planning CT and CBCT scans. 
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Purpose or Objective: Tumour sub-volumes for dose 
escalation can be defined using different PET tracers. This 
study compares hypoxic volumes defined by FMISO PET and 
metabolically active volumes defined by FDG PET for patients 
with advanced squamous cell carcinomas of the head and 
neck (SCCHN). 
 
Material and Methods: Imaging data of 14 patients was used, 
which were included in a phase II FMISO dose escalation 
study. Pre-therapy FMISO PET/CT images were acquired four 
hours post tracer injection. FDG PET/CT imaging was 
performed according to the institutional diagnostic protocol. 
The planning CT and the GTV of the primary tumour were 
available. Datasets were deformably co-registered using the 
CT images. Metabolically active sub-volumes were segmented 
in FDG PET images based on a source-to-background method 
with an adaptive threshold. Hypoxic sub-volumes were 
defined using a tumour-to-muscle threshold of 1.4. Expanding 
the volumes by an isotropic margin of five millimeters 
resulted in PTV-prim and potential dose escalation volumes 
PTV-FMISO and PTV-FDG. We analyzed the overlap between 
PTV-FMISO and PTV-FDG. 
 
Results: Mean dose escalation volumes were 19.7 cm³ (0.0-
57.3 cm³) for PTV-FMISO and 39.3 cm³ (17.5-91.9 cm³) for 
PTV-FDG. On average PTV-FDG covered 73.5% of PTV-FMISO 
(4.9-100.0%). Only for two out of fourteen patients (14%) 
PTV-FMISO was completely covered by PTV-FDG. Vice versa 
36.3% of PTV-FDG overlapped with PTV-FMISO (0.0-97.4%). 
PTV-prim from treatment planning was 111.1 cm³ (57.1-201.2 
cm³). Detailed results of the overlap analysis for all patients 
are given in Table 1. 
 
 
Conclusion: PTV-FDG typically covers PTV-FMISO only 
partially and is on average two times larger. Therefore, a 
dose escalation in the metabolically active sub-volume 
partially misses the hypoxic sub-volume. The large volume 
difference suggests that a substantially higher dose 
escalation is feasible in PTV-FMISO than in PTV-FDG. Clinical 
trials are required to compare the efficacy of both methods. 
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Purpose or Objective: Patients with locally advanced rectal 
cancer (LARC) are commonly treated with neoadjuvant 
chemoradiotherapy (CRT) followed by radical surgery. 
However, tumor responses vary considerably and about one 
third of the patients experience poor disease outcome due to 
metastatic progression. We aimed to investigate if apparent 
diffusion coefficients (ADCs) quantified from diffusion-
weighted MRI (DWMRI) predicted histologic tumor response to 
the neoadjuvant treatment and long-term survival. 
Recognizing the tumor heterogeneity we specifically aimed to 
explore if histogram analysis of tumor ADC may reveal more 
useful information than the commonly used mean ADC 
measure. 
 
Material and Methods: Data from 23 prospectively enrolled 
patients receiving induction neoadjuvant chemotherapy 
(NACT) followed by CRT and radical surgery was analyzed. 
DWMRI was acquired at baseline and after NACT. Tumor 
volumes contoured in T2-weighted MR images were 
transferred to tumor ADC maps calculated with b-values 300 
and 900 s/mm2, before ADCs were extracted from all tumor 
voxels and presented as histograms. The predictive 
information contained in the histograms was evaluated using 
receiver operating characteristic (ROC) curve analysis of each 
percentile from 1-100. Study endpoints were histologic tumor 
regression grade (TRG) and 5-year progression-free survival 
(PFS). 
 
Results: Using the change in tumor ADC from baseline to 
NACT completion, we identified a histogram area below 
median (20th–40th percentiles) to be associated with both 
TRG and PFS. By using the 20th percentile, an increase in 
